Efficacy of paclitaxel released from bio-adhesive polymer microspheres on model superficial bladder cancer

Journal of Urology

Volumn 171, Issue 3, 2004, Pages 1324-1329

  Le Visage, Catherine ^a   Rioux Leclercq, Nathalie ^a   Haller, Michael ^a   Breton, Pascal ^b   Malavaud, Bernard ^a,c   Leong, Kam ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRSOL   (France)

^c UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Bladder; Carcinoma, transitional cell; Drug delivery systems; Microspheres; Paclitaxel

Indexed keywords

DRINKING WATER; MALONIC ACID DERIVATIVE; MICROSPHERE; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; PACLITAXEL; POLY(METHYLIDENE MALONATE); POLYMER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARCINOMA IN SITU; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DISTRIBUTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SUSTAINED RELEASE PREPARATION; TRANSITIONAL CELL CARCINOMA; UROTHELIUM;

EID: 1542327741     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000103922.12319.59     Document Type: Article

References (20)

1. Alexandroff, A. B., Jackson, A. M., O'Donnell, M. A. and James, K.: BCG immunotherapy of bladder cancer: 20 years on. Lancet, 353: 1689, 1999
2. Nilsson, S., Ragnhammar, P., Glimelius, B., Nygren, P. and SBU-group. Swedish Council of Technology Assessment in Health Care: A systematic overview of chemotherapy effects in urothelial bladder cancer. Acta Oncol, 40: 371, 2001
3. Au, J. L., Kalns, J., Gan, Y. and Wientjes, M. G.: Pharmacologic effects of paclitaxel in human bladder tumors. Cancer Chemother Pharmacol, 41: 69, 1997
4. Nativ, O., Aronson, M., Medalia, O., Moldavsky, T., Sabo, E., Ringel, I. et al: Anti-neoplastic activity of paclitaxel on experimental superficial bladder cancer: in vivo and in vitro studies. Int J Cancer, 70: 297, 1997
5. Le Visage, C., Quaglia, F., Dreux, M., Ounnar, S., Breton, P., Bru, N. et al: Novel microparticulate system made of poly(methylidene malonate 2.1.2). Biomaterials, 22: 2229, 2001
6. Ito, N.: Early changes caused by N-butyl-N-(4-hydroxybutyl)nitrosamine in the bladder epithelium of different animal species. Cancer Res, 36: 2528, 1976
7. Yamamoto, S., Tatematsu, M., Yamamoto, M., Fukami, H. and Fukushima, S.: Clonal analysis of urothelial carcinomas in C3H/HeN ← → BALB/c chimeric mice treated with N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis, 19: 855, 1998
8. Wientjes, M. G., Badalament, R. A. and Au, J. L.: Penetration of intravesical doxorubicin in human bladders. Cancer Chemother Pharmacol, 37: 539, 1996
9. De Bruijn, E. A., Sleeboom, H. P., van Helsdingen, P. J., van Oosterom, A. T., Tjaden, U. R. and Maes, R. A.: Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling times. Int J Cancer, 51: 359, 1992
10. Song, D., Wientjes, M. G. and Au, J. L.: Bladder tissue pharmacokinetics of intravesical taxol. Cancer Chemother Pharmacol, 40: 285, 1997
11. Treat, J., Damjanov, N., Huang, C., Zrada, S. and Rahman, A.: Liposomal-encapsulated chemotherapy: preliminary results of a phase I study of a novel liposomal paclitaxel. Oncology, 15: 44, 2001
12. Jackson, J. K., Gleave, M. E., Yago, V., Beraldi, E., Hunter, W. L. and Burt, H. M.: The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel. Cancer Res, 60: 4146, 2000
13. Sharma, A., Mayhew, E. and Straubinger, R. M.: Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model. Cancer Res, 53: 5877, 1993
14. Konety, B. R., Lavelle, J. P., Pirtskalaishvili, G., Dhir, R., Meyers, S. A., Nguyen, T.-S. T. et al: Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. J Urol, 165: 253, 2001
15. Burnett, A. L., Calvin, D. C., Chamness, S. L., Liu, J. X., Nelson, R. J., Klein, S. L. et al: Urinary bladder-urethral sphincter dysfunction in mice with targeted disruption of neuronal nitric oxide synthase models idiopathic voiding disorders in humans. Nat Med, 3: 571, 1997
16. Le Visage, C., Couvreur, P., Mysiakine, E., Breton, P. Bru, N. and Fattal, E.: In vitro and in vivo evaluation of poly(methylidene malonate 2.1.2) microparticles behavior for oral administration. J Drug Target, 9: 141, 2001
17. Hurst, R. E. and Zebrowski, R.: Identification of proteoglycans present at high density on bovine and human bladder luminal surface. J Urol, 152: 1641, 1994
18. Johnson, J. W., Nayar, R., Killion, J. J., von Eschenbach, A. C. and Fidler, I. J.: Binding of liposomes to human bladder tumor epithelial cell lines: implications for an intravesical drug delivery system for the treatment of bladder cancer. Sel Cancer Ther, 5: 147, 1989
19. Bousquet, Y., Swart, P. J., Schmitt-Colin, N., Velge-Roussel, F., Kuipers, M. E., Meijer, D. K. et al: Molecular mechanisms of the adsorption of a model protein (human serum albumin) on poly(methylidene malonate 2.1.2) nanoparticles. Pharm Res, 16: 141, 1999
20. Knemeyer, I., Wientjes, M. G. and Au, J. L.: Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment. Cancer Chemother Pharmacol, 44: 241, 1999